Resources

Cognito Therapeutics Announces Spectris™ Demonstrates Durable Effects on Activities of Daily Living in the OVERTURE II Study

Cognito Therapeutics has positive non-invasive neuromod results

Cognito Therapeutics Announces Spectris™ OVERTURE OLE Study Data Supports Potential Disease Modification and Early Treatment in Alzheimer’s Disease

A New Headset Aims to Treat Alzheimer’s With Light and Sound

Cognito Therapeutics OVERTURE Clinical Trial in Alzheimer's Disease Published in Frontiers in Neurology

Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease